DelveInsight’s, “Leiomyosarcoma Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Leiomyosarcoma pipeline landscape. It covers the Leiomyosarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Leiomyosarcoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Leiomyosarcoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Leiomyosarcoma Pipeline Outlook

Key Takeaways from the Leiomyosarcoma Pipeline Report

• In February 2025:- PharmaMar– The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
• In February 2025:- Atara Biotherapeutics:- The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases. This is a multicenter, multicohort, open-label, single-arm, Phase 2 study to assess the efficacy and safety of tabelecleucel for the treatment of EBV-associated diseases
• DelveInsight’s Leiomyosarcoma Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading Leiomyosarcoma Companies such as Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis Oncology, Inc., and others.
• Promising Leiomyosarcoma Therapies such as Lurbinectedin, Doxorubicin, Unesbulin, Dacarbazine, Rucaparib, Nivolumab, Dinutuximab Beta, Zoledronic acid, Interleukin-2, and others.

Stay ahead with the most recent pipeline outlook for Leiomyosarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Leiomyosarcoma Approved Drugs

Leiomyosarcoma Emerging Drugs Profile

• ADI PEG20: Polaris Group

ADI-PEG 20 is a first-in-class therapeutic approach to deplete arginine and starve cancer cells. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, some cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Currently, it is in Phase III stage of clinical trial evaluation to treat Leiomyosarcoma.

• OR2805: OncoResponse

OR2805 is a fully human monoclonal antibody that targets CD163, an immune-suppressive receptor highly expressed on tumor-associated macrophages (TAMs). It was discovered using B cells derived from an elite responder to checkpoint inhibitor (CPI) therapy and is designed to reverse the immunosuppressive effect of TAMs, enhancing anti-tumor T-cell responses. In preclinical studies, OR2805 showed significant anti-tumor activity in lung cancer xenograft models in humanized mice and relieved the suppressive effect of M2c macrophages in coculture assays. OR2805 is currently being evaluated in a Phase I/II clinical trial to assess its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with Leiomyosarcoma. The trial includes a dose-escalation phase, expansion cohorts, and a biology cohort to evaluate potential biomarkers. OR2805 has the potential to improve anti-tumor T-cell responses by reversing the immunosuppressive effect of TAMs, making it a promising therapeutic strategy for treating advanced cancers.

The Leiomyosarcoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Leiomyosarcoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Leiomyosarcoma Treatment.
• Leiomyosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Leiomyosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Leiomyosarcoma market.

Explore groundbreaking therapies and clinical trials in the Leiomyosarcoma Pipeline. Access DelveInsight’s detailed report now! @ Leiomyosarcoma Treatment Drugs

Leiomyosarcoma Companies

Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis Oncology, Inc., and others.

Leiomyosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Leiomyosarcoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Leiomyosarcoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Leiomyosarcoma Market Drivers and Barriers

Scope of the Leiomyosarcoma Pipeline Report

• Coverage- Global
• Leiomyosarcoma Companies- Merck, Advenchen Laboratories, Trillium Therapeutics, PTC Therapeutics, PharmaMar, Philogen, EMD Serono, Incyte Corporation, Clovis Oncology, Inc., and others.
• Leiomyosarcoma Therapies- Lurbinectedin, Doxorubicin, Unesbulin, Dacarbazine, Rucaparib, Nivolumab, Dinutuximab Beta, Zoledronic acid, Interleukin-2, and others.
• Leiomyosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• LeiomyosarcomaTherapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Leiomyosarcoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Leiomyosarcoma Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Leiomyosarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Leiomyosarcoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Leiomyosarcoma Collaboration Deals
9. Late Stage Products (Phase III)
10. AL-3818: Advenchen Laboratories
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. OR2805: OncoResponse
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Leiomyosarcoma Key Companies
20. Leiomyosarcoma Key Products
21. Leiomyosarcoma- Unmet Needs
22. Leiomyosarcoma- Market Drivers and Barriers
23. Leiomyosarcoma- Future Perspectives and Conclusion
24. Leiomyosarcoma Analyst Views
25. Leiomyosarcoma Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight